Eli Lilly (LLY)

Competition among the makers of weight loss treatments is intensifying.

Viking Therapeutics reported positive Phase 2 results for VK2735, showing significant weight loss and safety in obesity patients versus placebo.

Shares lost more than a third of their value after Viking unveiled mixed results for its oral VK2735.

The healthcare industry is one of the laggards of 2025.

U.S. stock futures were fluctuating on Tuesday following mostly unchanged moves from Monday. Futures of major benchmark indices were mixed.

Eli Lilly's rare 40-year bond sparks talk of a Viking Therapeutics (VKTX) acquisition. Experts say LLY is "setting up for something BIG."

GoodRx stock rose 5.08% after it partnered with Novo Nordisk to offer Ozempic and Wegovy at a flat $499 monthly price for self-paying patients.

GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies across the U.S.

Novo Nordisk stock looks so cheap, any good news at all can make it pop.

This might be a wonderful entry point for long-term investors.

This ETF has outperformed the S&P 500 handily over various multi-year periods.

The drugmaker has a major catalyst on the way.

The drugmaker's recent dip could also be a buying opportunity.

Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years.

In the face of a frothy market, Jim Cramer encourages investors to stay the course, highlighting numerous positive stock narratives that counterbalance the market's irrationality.

Viking Therapeutics' dual-formulation obesity drug could be the David to Lilly's Goliath.

The Vanguard Dividend Appreciation ETF has an excellent balance of growth, income, and value stocks.

It seems to be holding off on price adjustments demanded by President Trump.

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.2% in the afternoon session after the stock extended its positive momentum partly fueled by reports of major insider buying by top executives, including the CEO, which is often seen as a strong vote of confidence. Additionally, news that the company has signed a multi-billion dollar deal with an AI health tech company (Superluminal) to discover and develop new obesity medicines also contributed to the positive sentiment. Finally, the company's decision to increase the price of its popular diabetes and weight-loss drug Mounjaro in the UK, in response to US political pressure, was also seen as a positive for future revenue.

Eli Lilly's pricing strategy for GLP-1 drugs is expected to have minimal margin impact, with BofA reaffirming a $900 price target.

Major tech-heavy indices edged lower from record highs by midday Friday in New York, as investors adopted a cautious stance ahead of the Trump-Putin meeting and after data showed a dip in consumer confidence alongside mounting inflation concerns.

Several companies, including Palantir and Eli Lilly, have raised guidance, reflecting positivity surrounding their results. Let’s take a closer look at what drove the strong quarters.